Last reviewed · How we verify
NGX-1998
At a glance
| Generic name | NGX-1998 |
|---|---|
| Sponsor | NeurogesX |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of NGX-1998 for the Treatment of Postherpetic Neuralgia (PHASE2)
- A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGX-1998 CI brief — competitive landscape report
- NGX-1998 updates RSS · CI watch RSS
- NeurogesX portfolio CI